Lenalidomide

Where the papers sit

17 papers from the last 6 months study lenalidomide directly · updated from PubMed 5 Oct 2026

• Multiple Myeloma Therapy

  Multiple myeloma treatment is moving toward daratumumab-containing induction and maintenance strategies built around bortezomib, lenalidomide, and dexamethasone. Progression-free survival and minimal residual disease guide comparisons of intensified combinations, fixed-duration therapy, and continuous maintenance. Infection risk, dosing differences, and other safety outcomes remain important trade-offs. IMiD-resistant disease is prompting molecular glue degraders and other approaches beyond lenalidomide.

  11 papers · 64.7%

• B-Cell Lymphoma Therapy

  B-cell lymphoma treatment is expanding lenalidomide and rituximab combinations with the bispecific antibody epcoritamab. In follicular lymphoma, studies test this strategy in both relapsed disease and first-line therapy against usual care, with progression-free survival as a key endpoint. Long-term follow-up continues to define the durability of lenalidomide plus rituximab. R-CHOP-based comparisons extend the question to high-risk diffuse large B-cell lymphoma.

  4 papers · 23.5%

• Cereblon Structure and Targeting

  Cereblon characterization is being linked to lenalidomide-based molecular targeting. Backbone resonance assignments define the thalidomide-binding domain, while rhenium and technetium-99m η6-arene sandwich complexes explore radiolabeled derivatives. Chelator-free radiolabeling supports evaluation of these compounds as potential imaging or targeted agents. Their binding properties, stability, and in vivo performance remain open questions.

  2 papers · 11.8%